A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity

Leo I. Gordon, Mary Young, Edie Weller, Thomas M. Habermann, Jane N. Winter, John Glick, Chirantan Ghosh, Patrick Flynn, Peter A. Cassileth

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences